Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Conditions: Stage III Breast Cancer|Stage IV Breast Cancer|Stage III Lung Cancer|Stage IV Lung Cancer|AML|Multiple Myeloma in Relapse|Carcinoma|Carcinoma, Pancreatic|Carcinoma of Lung|Carcinoma, Non-Small-Cell Lung|Carcinoma Breast|Carcinoma Prostate|Carcinoma, Hepatocellular|Carcinoma, Renal Cell|Carcinoma, Neuroendocrine|Carcinoma, Small Cell Lung|Carcinoma, Ovarian|Carcinoma Bladder|Carcinoma of Esophagus|Carcinoma Cervix|Carcinoma, Thymic|Carcinoma, Ductal|Carcinoma of the Head and Neck|Carcinoma of the Lip|Carcinoma of the Oral Cavity|Carcinoma of Unknown Primary|Carcinoma of the Skin|Carcinoma of the Anus|Carcinoma of the Larynx|Carcinoma of the Penis|Carcinoma of the Oropharynx|Carcinoma of the Appendix|Carcinoma of the Paranasal Sinus|Carcinoma of the Vulva|Malignant Pleural Effusion|Malignant Ascites|Mesothelioma|Cholangiocarcinoma
Sponsor: Travera Inc